Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Guardant Health, Inc. (Nasdaq: GH), a precision oncology company based in Palo Alto, California. Through these filings, investors and analysts can review the company’s official disclosures about its capital structure, governance, and key events related to its blood and tissue tests, real-world data activities, and AI analytics in cancer care.
Guardant Health’s common stock is registered on The Nasdaq Global Select Market under the symbol GH, as noted in its Form 8-K filings. The company files current reports on Form 8-K to describe material events, such as public offerings of common stock, private offerings of convertible senior notes, results of stockholder meetings, financial results announcements, and board appointments. These documents outline details like underwriting agreements, convertible note terms, and voting outcomes at annual meetings.
In addition to Form 8-K reports, Guardant Health files annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain more extensive information about its business, risk factors, and financial statements. Proxy statements on Schedule 14A provide further detail on governance matters and executive compensation. Together, these filings offer a regulatory record of how the company finances its operations, manages its corporate governance, and communicates significant developments to the market.
On Stock Titan, Guardant Health’s SEC filings are updated as they are made available through the EDGAR system. AI-powered tools can help summarize long documents, highlight key terms in offerings and note indentures, and make it easier to locate information on topics such as capital raises, voting results, and reporting obligations. This page is intended as a convenient starting point for reviewing Guardant Health’s regulatory disclosures in one place.
Guardant Health director Vijaya Gadde received new equity compensation grants on June 18, 2025, consisting of:
- Stock options to purchase 6,833 shares of common stock at an exercise price of $50.57 per share, expiring June 18, 2035
- 4,203 Restricted Stock Units (RSUs) with no exercise price
Both the stock options and RSUs will fully vest on the earlier of: (1) the one-year anniversary of the grant date (June 18, 2025) or (2) the date of the next annual stockholders meeting. This equity compensation package appears to be part of standard director compensation. The Form 4 was filed by John G. Saia as attorney-in-fact for Vijaya Gadde on June 20, 2025.
Guardant Health Director Ian T. Clark reported multiple securities transactions on June 17-18, 2025:
- Disposed of 6,672 shares of common stock at an average price of $48.38 per share from the Thornton-Clark Family Trust
- Received a new stock option grant for 6,833 shares with exercise price of $50.57, vesting in full on June 18, 2025 or next annual stockholders meeting
- Granted 5,092 restricted stock units (RSUs) vesting in full on June 18, 2025 or next annual stockholders meeting
Following these transactions, Clark retains 9,851 shares indirectly through the family trust, plus the new equity awards. The stock sale was executed in multiple transactions within a $0.03 price range.
Guardant Health, Inc. (GH) filed a Form 144 notice for a planned sale of restricted stock that recently vested. The filing discloses that 3,213 shares of GH common stock are expected to be sold through broker Charles Schwab & Co., Inc. on or about 18 June 2025. The estimated aggregate market value of the proposed sale is $158,947. Compared with the company’s 123,888,045 shares outstanding, the transaction represents roughly 0.0026 % of total shares, indicating a de-minimis impact on the public float.
The seller—identified in the filing as Musa Tariq—acquired the shares on 15 June 2025 via the lapse of restrictions on equity compensation. Over the past three months Mr. Tariq has sold an additional 348 shares of Guardant Health stock across three transactions, generating $14,910 in gross proceeds. No relationship to the issuer is specified in the document, and the form states that the filer is unaware of any non-public material adverse information.
Because Form 144 covers proposed sales under Rule 144 and does not obligate the insider to complete the trade, investors typically view such filings as information events rather than firm commitments. Given the small size of the sale relative to Guardant Health’s market capitalization, the filing is unlikely to exert material pressure on share price but does provide incremental insight into insider trading intentions.
FAQ
What is the current stock price of Guardant Health (GH)?
What is the market cap of Guardant Health (GH)?
